Furthermore, CCS1477, an inhibitor of p300/CBP bromodomain, inhibits proliferation and decreases AR- and C-MYC–regulated gene expression, modulated KLK3/PSA concentration, and has shown promise for the treatment of patients with advanced prostate cancer. Here, MYC is linked to prostate cancer.